Johnson & Johnson‘s (NYSE:JNJ) Cerenovus is discontinuing production of Codman pumps designed to deliver targeted chemotherapy to the liver for patients with liver cancer, according to a New York Times report.
The devices are designed to be implanted in the abdomen to deliver chemotherapy directly to the liver to treat cancer that has spread to the area, generally from the colon or rectal tumors, according to the report.
Read the whole story on our sister site, Drug Delivery Business
The post Report: J&J’s Cerenovus to discontinue Codman liver cancer pump appeared first on MassDevice.
from MassDevice https://ift.tt/2HvF26x
Cap comentari:
Publica un comentari a l'entrada